ARMATA PHARMACEUTICALS INC (ARMP)
Health Care · biotechnology · NYSE American
Armata Pharmaceuticals is pioneering the development of precision bacteriophage therapies as a targeted alternative to traditional broad-spectrum antibiotics for drug-resistant bacterial infections.
What ARMATA PHARMACEUTICALS INC does
Armata Pharmaceuticals is a clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Its proprietary platform leverages high-purity, potency-engineered bacteriophages that target and kill specific bacteria while preserving the human microbiome. The company is advancing lead clinical candidates for Pseudomonas aeruginosa and Staphylococcus aureus infections.
Recent developments
Armata plans to initiate a pivotal Phase 3 superiority study for AP-SA02 in complicated S. aureus bacteremia in the second half of 2026. The FDA has granted Fast Track designation to AP-SA02 and agreed to an initial pediatric study plan, while the company also secured an additional $2.5 million in non-dilutive funding from the U.S. Department of War.
From ARMATA PHARMACEUTICALS INC's filing of 2026-08-12.
Themes: bacteriophage therapeutics, antibiotic resistance / superbugs, precision medicine, infectious disease, microbiome preservation
Fundamentals
- Price$3.86 as of 2026-10-08 close
- Market cap$144M as of 2026-08-06 (share count; price 2026-10-08)
- 1-year return+19.9% 2025-10-08 close $3.22 → 2026-10-08 close $3.86
- P/En/a negative earnings
- Debt / equity1.38 as of 2026-09-03
- Revenue growth (YoY)+10.7% as of 2026-09-03
- Beta0.36 as of 2026-09-03
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
How ARMP compares in its sector
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Dividend coverage
Not assessed — last reported dividend predates the accounts. The most recent fiscal year in which ARMP reported a dividend payment is FY2016, while its reported financial statements run through FY2025. Coverage is therefore not assessed for the latest year — an FY2016 ratio would not describe ARMP today.
Coverage is derived from reported SEC EDGAR XBRL figures, comparing dividends paid against net income and free cash flow for the SAME fiscal year. It is not shown here because the latest fiscal year with a reported dividend payment (FY2016) is older than the latest year of reported financial statements (FY2025), so any ratio would describe an out-of-date year. Informational only — not financial advice.
How ARMATA PHARMACEUTICALS INC looks technically
ARMATA PHARMACEUTICALS INC (ARMP) is trading 46.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 61 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It made a new 20-day low about 6 trading days ago. It is 76.4% below its highest point of the past year. Trading volume is unusually light — only about 25% of its 30-day average.
Trend
7
| Distance from the 200-day | it is trading 46.9% below its 200-day average, the long-term trend line — a long-term downtrend | -47.0% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.61 | $4.61 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $7.28 | $7.28 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing low 7 calendar days ago — the swings before that are what the structure reading is measured on | 7 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 61 trading days ago — a "death cross", a bearish long-term signal | 61 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) | 10.3 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 43, neither overbought (above 70) nor oversold (below 30) | 43.3 |
|---|---|---|
| Position in its 14-day range | it is trading around the middle of its 14-day range ($3.28 to $4.56) — its "stochastic" reading is 45 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 45.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $16.34 | $16.34 |
|---|---|---|
| From the 52-week high | it is 76.4% below its 52-week high (its highest price of the past year) | -76.4% |
| Above the 52-week low | it is 24.9% above its 52-week low (its lowest price of the past year) | +24.9% |
| Below the 52-week high | it is 76.4% below its highest point of the past year | 76.4% |
| Since a 20-day breakout | it made a new 20-day low about 6 trading days ago | 6 sessions |
| Since a 55-day breakout | it made a new 55-day low about 6 trading days ago | 6 sessions |
| All-time high | its highest closing price on record is $1960000.00 (set on 2000-02-18) | $1960000.00 |
| Given back of the 52-week move | over the past year its closes ranged ($3.14 to $14.80), and it has given back almost all of its rise from last year’s low — 94% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $7.22 to $7.59. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 93.8% |
| From the all-time high | it is 100.0% below its all-time high | -100.0% |
| Nearest price level | it is trading 29.5% above a support level at $2.72 — a price it turned at three times since 2025-05-20, most recently on 2025-08-19. Since 2024-10-08 it has 6 such levels below the current price and 3 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -29.5% |
| All-time low | its lowest closing price on record is $0.83 (set on 2022-12-28) | $0.83 |
| Above the all-time low | it is 365.1% above its all-time low | +365.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4074 between its high and its low — about 10.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4074 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $2.90 and $5.12 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $2.90 – $4.01 – $5.12 |
| Typical daily range (% of price) | its price moves about 10.6% in a typical session — among the most volatile in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 10.6% |
| Stretch from the 200-day average | it is trading 8.4 daily ranges below its 200-day average price (47.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 8.4 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 25% of its 30-day average | 0.25× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
3
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|---|---|
| Since a bullish engulfing | today it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | today |
| Since a bearish engulfing | 5 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 5 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-10-08 0.5% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.5% |
|---|---|---|
| Open gap | it gapped 2.7% above the previous close 4 sessions ago and has not traded back through the level it left behind at 3.31 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.7% |
| Gap filled | a 2.1% gap down opened on 2026-09-28 has been "filled" 8 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 8 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 34.7 percentage points (the stock lost 33.7% while the market gained 1.0%) | -34.7% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 28.1 percentage points (the stock lost 24.3% while the market gained 3.8%) | -28.1% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 80.9 percentage points (the stock lost 63.4% while the market gained 17.5%) | -80.9% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.9 percentage points (the stock gained 19.9% while the market gained 15.0%) | +4.9% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 17.8% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -20.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 39% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $6.33 — a volume-weighted average of daily closes over 192 sessions, not a true tick-by-tick VWAP. | -39.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 22% below the average price paid since it last reported on 2026-08-12 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.97 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | -22.3% |
Price levels it has turned at before
ARMP last closed at $3.86 on 2026-10-08. Since 2024-10-08 it has turned at 6 prices below its last close and 3 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $2.72 | Support | 29.5% below the last close | turned there three times · 2025-05-20 to 2025-08-19 |
| $2.39 | Support | 38.1% below the last close | turned there three times · 2024-11-27 to 2025-09-02 |
| $2.29 | Support | 40.5% below the last close | turned there four times · 2024-12-11 to 2025-03-21 |
| $5.69 | Resistance | 47.3% above the last close | turned there three times · 2026-01-15 to 2026-08-25 |
| $6.62 | Resistance | 71.5% above the last close | turned there twice · 2025-12-29 to 2026-09-14 |
| $7.43 | Resistance | 92.6% above the last close | turned there twice · 2025-11-20 to 2026-03-20 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bullish (12/26/9) · trendless / choppy (low ADX) · lagging the market · Printed a bullish engulfing pair | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · volume and relative volume
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.00 mean, 1=Strong Buy…5=Strong Sell) — 2 analysts
- Mean price target$17.50 range $15.00 – $20.00
Analyst estimates, as of 2026-10-05. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Key risks (from latest filing)
["Significant reliance on continued non-dilutive funding and capital raises to support expensive Phase 3 clinical trials.","High clinical trial failure risk and uncertainty regarding regulatory approval for novel bacteriophage-based therapies.","Manufacturing complexities and the challenge of scaling cGMP production of high-titer, high-purity phage cocktails."]
What changed in the latest 10-Q
AI-assisted comparison of ARMP's 10-Q filed 2026-08-12 against the prior one filed 2026-05-13.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds the sentence: 'Our demonstrated ability to reproducibly produce high titer functional phages of the highest purity allows us to administer our phages intravenously opening up a future of potential broad use across direct injection into privileged and closed spaces.'
- Removed:
- Older filing contains text after 'AP-PA02 exposures were generally consistent across subjects.' that continues: 'Additionally, bacterial levels of P. aeruginosa in the sputum measured at several timepoints suggest improvement in bacterial load reduction for subjects treated with AP-PA02 at the end of treatment as compared to placebo after ten days of dosing. In addition, a correlation was seen between increasing phage dose (higher AP-PA02 exposures) and reduction in the bacterial load, supporting the biologic plausibility of a bacterial specific mechanism of action and creating the opportunity for phage as a therapeutic alternative to inhaled an...' This text does not appear in the newer filing.
- Reworded:
- Older filing states the Common Stock 'is traded on the NYSE American exchange under the symbol "ARMP."'; newer filing states it 'is traded on the NYSE American under the symbol "ARMP."' (removes the word 'exchange').
- Older filing begins Overview discussion with 'We see bacteriophages as a potentially safer and effective alternative...' and 'an essential response'; newer filing changes to 'We view bacteriophages as a potentially safer and more effective critical future alternative...' and 'a core response'.
- Older filing describes phages as having 'a powerful and highly differentiated mechanism of action'; newer filing changes to 'a powerful mechanism of action highly differentiated from all current antibiotics'.
- Older filing includes sentence 'There have been significant advances in understanding the importance of preserving our gut microbiome which is substantially altered by broad-spectrum antibiotics, uniquely positioning phage therapy as a novel precision-targeted antibacterial treatment.'; newer filing does not include this sentence and instead has a similar but not this wording.
- Older filing reads 'treatment emergent adverse event profile'; newer filing changes to 'treatment-emergent adverse event profile'.
- Older filing reads 'Pharmacokinetics findings confirm'; newer filing changes to 'Pharmacokinetic findings confirm'.
- Notes:
- The newer filing text appears to be cut off mid-sentence ending at 'Add', preventing a full comparison of any subsequent content.
- The older filing text also appears to be cut off mid-word ending at 'an', so changes beyond that truncation point cannot be assessed.
Risk Factors
- Added:
- In the filing dated 2026-08-12, Exhibit 10.2 (Employment Letter Agreement, dated July 17, 2026, by and between the Company and David House, incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed July 20, 2026) was added.
- In the filing dated 2026-08-12, Exhibit 10.3 (Amendment No. 1, dated July 17, 2026, to Employment Letter Agreement dated June 1, 2024, by and between the Company and Pierre Kyme, incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed July 20, 2026) was added.
- Removed:
- In the filing dated 2026-05-13, Item 5 included a 'Credit and Security Agreement' subsection describing the May 2026 Credit Agreement entered into on May 12, 2026 with Innoviva Strategic Opportunities LLC; that subsection is absent from the filing dated 2026-08-12.
- In the filing dated 2026-05-13, Exhibit 10.1 (First Amendment, dated January 23, 2026, to Credit and Security Agreement dated March 12, 2025) was removed from the exhibit list in the filing dated 2026-08-12.
- In the filing dated 2026-05-13, Exhibit 10.2 (Second Amendment, dated January 23, 2026, to Credit and Security Agreement dated March 4, 2024) was removed from the exhibit list in the filing dated 2026-08-12.
- In the filing dated 2026-05-13, Exhibit 10.3 (Fourth Amendment, dated January 23, 2026, to Credit and Security Agreement dated July 10, 2023) was removed from the exhibit list in the filing dated 2026-08-12.
- In the filing dated 2026-05-13, Exhibit 10.4 (Fifth Amendment, dated January 23, 2026, to Secured Convertible Credit and Security Agreement dated January 10, 2023) was removed from the exhibit list in the filing dated 2026-08-12.
- In the filing dated 2026-05-13, Exhibit 10.5 (Amendment No. 2, dated January 23, 2026, to Second Amended and Restated Voting Agreement dated February 9, 2022) was removed from the exhibit list in the filing dated 2026-08-12.
- Reworded:
- In the filing dated 2026-05-13, Item 5's insider trading disclosure referenced 'the three months ended March 31, 2026'; in the filing dated 2026-08-12, it references 'the three months ended June 30, 2026'.
- In the filing dated 2026-05-13, Exhibit 10.6 described the Credit and Security Agreement dated May 12, 2026; in the filing dated 2026-08-12, that same agreement appears as Exhibit 10.1.
- In the filing dated 2026-05-13, the signature block listed only Deborah L. Birx as signatory; in the filing dated 2026-08-12, both Deborah L. Birx (CEO) and David House (CFO) are listed as signatories.
- Notes:
- The Risk Factors section text itself (the first paragraph under Item 1A) is identical between the two filings, both stating no material changes from the 2025 Form 10-K.
- The comparison includes Item 2 through Item 6 and exhibit lists because those sections appear within the provided 'Risk Factors' source text block despite being outside the strict Risk Factors section heading.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales are on record for ARMP — recent Form 4 activity was compensation-related (awards, option exercises, or tax withholding), not open-market buying or selling.
View full insider trading history → View SEC Form 3/4/5 filingsOnly open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ARMP as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 738,268
- Reported value $4,783,979
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about ARMP's institutional holders → See what each manager we track holds →
Short interest (FINRA)
ARMP had 963,383 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ARMP had 2.59% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 1.65 days to cover at the same settlement.
- Reported short interest (shares) 963,383
- Short interest (% of shares outstanding) 2.59%
- Prior settlement (shares) 885,291
- Reported change 8.82%
- Days to cover (reported) 1.65
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Adaptive Phage Therapeutics
- Pherecydes Pharma
- ContraFect (CFRX)
- Summit Therapeutics (SMMT)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ARMP vs…
ARMATA PHARMACEUTICALS INC is found in…
Frequently asked questions
What does ARMATA PHARMACEUTICALS INC (ARMP) do?
Armata Pharmaceuticals is a clinical-stage biotechnology company developing pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Its proprietary platform leverages high-purity, potency-engineered bacteriophages that target and kill specific bacteria while preserving the human microbiome. The company is advancing lead clinical candidates for Pseudomonas aeruginosa and Staphylococcus aureus infections.
What sector is ARMATA PHARMACEUTICALS INC (ARMP) in?
ARMATA PHARMACEUTICALS INC (ARMP) is classified in the Health Care sector. Its industry is biotechnology. It trades on NYSE American.
Who are ARMATA PHARMACEUTICALS INC's (ARMP) competitors?
Notable peers of ARMATA PHARMACEUTICALS INC (ARMP) include Adaptive Phage Therapeutics, Pherecydes Pharma, ContraFect and Summit Therapeutics. This peer set is informational only — not financial advice.
Is ARMATA PHARMACEUTICALS INC (ARMP) overbought or oversold right now?
ARMATA PHARMACEUTICALS INC (ARMP) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 43, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ARMP come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.